- Tarn SH, Sassoli PM, Jordan RE et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha (v)beta3 integrins. Circulation 1998; 98: 1085-1091.
- Jenkins LA, Lau S, Crawford M, Keung K. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998; 31: 1214-1215.
- Berkowitz SD, Sane DC, Sigmon KN et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the prevention of ischemic complications. EPIC study group. J Am Coll Cardiol 1998; 32: 311-319.
- Edward TA Fry MD. Readministration of abciximab in percutaneous coronary intervention. J Invas Cardiol 1999; 11: 251-258.
- Joseph T, Marco J, Gregorini L. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Clin Cardiol 1998; 11: 851-852.
- Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999; 61: 205-208.
- Bednar B, Bednar RA, Cook JJ et al. Drug-dependent anti-bodies against GP IIb/IIIa induced thrombocytopenia (abstr). Circulation 1996; 94(suppl I): 1-99.
- Berkowitz SD, Sane DC, Sigmon KN et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am CoIl Cardiol 1998; 32: 311-319.
- Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
- Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
- Demasi R, Bode AP, Knupp C et al. Heparin-induced thrombocytopenia. Am Surg 1994; 60: 26-29.
- Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993; 305: 208-215.
- Visentin GP, Ford SE, Scott JP et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
- Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost 1992; 68: 95-96.
- Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
- Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo ltaliano Malattie Ematologiche Maligne dell Adulto. N Engl J Med 1997; 337: 1870-1875.
- Wandt H, Frank M, Ehninger G et al. Safety and cost effectiveness of 10×10(9)/L trigger for prophylactic platelet transfusions compared with traditional 20×10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601-3606.
- Gil-Fernandez J, Alegre A, Fenandez-Villalta M et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18: 931-935.
- Sagmeister M, Oec E, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124-3126.
- Harkness DR, Byrnes JJ, Lian E et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246: 1931-1933.
- Lind SE. Thrombocytopenic purpura and platelet transfusions (letter). Ann Intern Med 1987; 106: 478.
- Burgess JK, Lopez JA, Berndt MC et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998; 92: 2366-2373.
- Contre S. Heparin induced thrombocytopenia. UpToDate 2001; 9.1: 1-9. (see www.uptodate.com)
- Brieger DB, Mak KH, Kohke-Merchant K, Topol EJ. Heparin induced thrombocytopenia. J Am Coll Cardiol 1998; 31: 1449-1459.
- Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk of heparin induced thrombocytopenia. Blood 2000; 96: 1703-1708.
Delayed thrombocytopenia following abciximab therapy
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.